Glomerulonephritis Cell Models for Research

Glomerulonephritis (GN) comprises a heterogeneous group of immune-mediated and genetic disorders affecting the glomerulus, leading to proteinuria, hematuria, and progressive kidney failure. According to the Global Burden of Disease Study 2019, chronic kidney disease (CKD) affects over 850 million individuals worldwide, with glomerulonephritis accounting for approximately 10-15% of cases progressing to end-stage renal disease (ESRD) in high-income countries. The incidence of primary glomerulonephritis is estimated at 2-10 per 100,000 person-years globally, with significant regional variation: IgA nephropathy is most common in Asia (40-50% of primary GN), while focal segmental glomerulosclerosis (FSGS) and membranous nephropathy predominate in Western populations. Key risk factors include genetic predisposition (e.g., APOL1 risk variants in individuals of African ancestry), infections (streptococcal, HIV, hepatitis B/C), autoimmune diseases (lupus, ANCA-associated vasculitis), and environmental exposures. Five-year renal survival varies by subtype: untreated rapidly progressive GN has a 5-year ESRD risk exceeding 50%, whereas steroid-sensitive minimal change disease achieves >90% remission. According to the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program, kidney and renal pelvis cancers (often secondary to chronic GN) have a 5-year relative survival of 76.5% overall, dropping to 14.3% for distant metastases, underscoring the need for early intervention in glomerular disease.

Glomerulonephritis is an ideal disease for mechanistic studies due to its well-defined genetic subtypes, accessible public datasets, and clear unmet need for targeted therapies. Key advantages include:

• • Heterogeneous but genetically tractable subtypes: monogenic forms (e.g., NPHS1, NPHS2, WT1, COL4A3/4/5 mutations) provide clear targets for CRISPR modeling.
• • Rich public data resources: transcriptomic and genomic data from the Nephrotic Syndrome Study Network (NEPTUNE), the European Renal cDNA Bank, and the Genotype-Tissue Expression (GTEx) project enable target discovery.
• • Open questions: How do podocyte-specific gene mutations disrupt the glomerular filtration barrier? What are the mechanisms of immune complex deposition in autoimmune GN? Which pathways drive progression to fibrosis?
• • CRISPR screens in podocytes and mesangial cells can identify modifiers of proteinuria and glomerulosclerosis.
• • Isogenic cell models allow dissection of single-gene contributions to disease phenotypes, facilitating drug target validation.

Although glomerulonephritis is not a malignant disease, several pathogenic pathways overlap with cancer-related signaling and can be modeled using gene-edited cells. Key pathways include:

1. Immune complex deposition and complement activation:

• • Circulating immune complexes deposit in the glomerulus, activating the classical complement pathway (C1q, C4, C3).
• • Alternative pathway dysregulation (e.g., factor H mutations) leads to C3 glomerulopathy.
• • Resulting membrane attack complex (C5b-9) damages podocytes and endothelium.

2. Podocyte injury and cytoskeletal remodeling:

• • Mutations in NPHS1 (nephrin), NPHS2 (podocin), and ACTN4 (alpha-actinin-4) disrupt the slit diaphragm.
• • Rho GTPase signaling (RhoA, Rac1, Cdc42) regulates podocyte foot process effacement.
• • Autophagy impairment leads to podocyte apoptosis and loss.

3. TGF-beta and fibrotic signaling:

• • TGF-beta1 activates SMAD2/3, driving mesangial cell proliferation and extracellular matrix accumulation.
• • Connective tissue growth factor (CTGF) and platelet-derived growth factor (PDGF) amplify fibrosis.
• • Epithelial-to-mesenchymal transition (EMT) of podocytes contributes to glomerulosclerosis.

4. Inflammatory cytokine networks:

• • NF-kB and JAK/STAT pathways mediate cytokine production (TNF-alpha, IL-6, IL-1beta).
• • Th17/Treg imbalance promotes autoimmune GN.
• • B-cell activating factor (BAFF) supports autoantibody production.

The following table summarizes high-frequency genetic alterations in glomerulonephritis subtypes, compiled from ClinVar, COSMIC, and published cohort studies. Frequencies refer to the proportion of patients with the specific subtype carrying the alteration.

Note: Frequencies are approximate and vary by population and diagnostic criteria. Data from ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and COSMIC (https://cancer.sanger.ac.uk/cosmic).

Glomerulonephritis involves complex deregulation of signaling networks. Key nodes and pathways include:

• • PI3K/AKT/mTOR pathway:
• • Activated in podocytes and mesangial cells in response to growth factors.
• • Promotes cell survival, hypertrophy, and matrix production.
• • PTEN loss amplifies AKT signaling, worsening proteinuria.
• • MAPK/ERK pathway:
• • Activated by mechanical stress and cytokines.
• • Drives mesangial proliferation and inflammation.
• • ERK1/2 inhibitors reduce proteinuria in experimental models.
• • Wnt/beta-catenin pathway:
• • Upregulated in podocytes during injury.
• • Induces EMT and apoptosis.
• • DKK1 (Wnt antagonist) is downregulated in FSGS.
• • NF-kB pathway:
• • Central to inflammatory gene expression (TNF-alpha, IL-6, MCP-1).
• • Activated by immune complexes and TLR signaling.
• • NF-kB inhibitors show efficacy in lupus nephritis models.
• • JAK/STAT pathway:
• • Mediates cytokine signaling (IL-6, IFN-gamma).
• • JAK2 mutations are rare but STAT3 activation is common in proliferative GN.
• • JAK inhibitors are in clinical trials for lupus nephritis.
• • Rho GTPase signaling:
• • RhoA/ROCK activation causes podocyte foot process effacement.
• • Rac1 is protective in some contexts.
• • ROCK inhibitors (e.g., fasudil) reduce proteinuria in animal models.

Several cell lines and organoid models are used to study glomerulonephritis. The table below lists commonly used lines with their origin and key mutations.

Organoid advantages: Kidney organoids derived from induced pluripotent stem cells (iPSCs) recapitulate glomerular architecture and allow patient-specific mutation modeling. They enable study of podocyte injury, immune cell interactions, and drug responses in a more physiological context. However, organoids lack a functional vasculature and immune system, limiting their utility for autoimmune GN.

Note: Cell lines are available from commercial sources and public repositories such as ATCC and ECACC (names mentioned for reference only; no endorsement).

Animal models are essential for studying glomerulonephritis pathogenesis and testing therapies. Key models include:

• • Genetic models (GEMM):
• • NPHS1 knockout mice: develop congenital nephrotic syndrome with massive proteinuria.
• • NPHS2 knockout mice: severe proteinuria and podocyte foot process effacement.
• • APOL1 transgenic mice: recapitulate FSGS-like lesions when expressing risk variants.
• • COL4A3 knockout mice: model Alport syndrome with progressive glomerulosclerosis.
• • Induced models:
• • Nephrotoxic serum nephritis (NTN): passive transfer of anti-glomerular basement membrane antibodies induces crescentic GN.
• • Lupus nephritis models: MRL/lpr and NZB/W F1 mice develop spontaneous autoimmune GN.
• • Streptozotocin-induced diabetic nephropathy: models secondary GN.
• • Adriamycin-induced nephropathy: podocyte injury and FSGS-like lesions.
• • Patient-derived xenografts (PDX):
• • Limited use due to lack of immune system, but human kidney tissue xenografts in immunodeficient mice can model immune complex deposition.
• • Humanized models:
• • Mice with human immune system components (e.g., NSG-SGM3) engrafted with human hematopoietic stem cells can model autoimmune GN.

These models are available from commercial breeders and research consortia (e.g., Jackson Laboratory, but no endorsement).

CRISPR/Cas9 gene editing has revolutionized the creation of isogenic cell models for glomerulonephritis research. These models enable precise dissection of gene function and drug target validation.

Examples of gene-edited cell models:

• • Tumor suppressor knockout: CRISPR knockout of NPHS2 in human podocytes leads to loss of podocin, disrupted slit diaphragm, and increased permeability to albumin. This model is used to screen for compounds that restore barrier function.
• • Oncogenic point-mutation knock-in: Knock-in of the APOL1 G1 risk variant (S342G/I384M) in podocytes induces mitochondrial dysfunction and cell death, mimicking FSGS. This isogenic pair (wild-type vs. mutant) is ideal for drug screening.
• • Reporter lines: Podocytes engineered with a fluorescent reporter under the control of the NPHS1 promoter allow real-time monitoring of podocyte injury and recovery.
• • Knockout of COL4A3 in HEK293 cells: Models Alport syndrome and enables study of basement membrane assembly.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing, which can be time-consuming and variable. These models are validated for off-target effects and are provided with detailed characterization data. Researchers can obtain custom CRISPR knockout and knock-in lines tailored to specific glomerulonephritis targets, ensuring reproducibility and consistency across studies.

Gene-edited cell models are powerful tools for functional genomics in glomerulonephritis. By systematically knocking out or knocking in specific genes, researchers can validate their role in disease pathogenesis.

Examples:

• • CRISPR knockout of TRPC6 in podocytes: Validated its role in calcium influx and podocyte injury. Knockout cells show reduced calcium signaling and protection against injury-induced apoptosis.
• • Knock-in of WT1 mutations: Recapitulates Denys-Drash syndrome phenotypes, including impaired podocyte differentiation and increased apoptosis.
• • Genome-wide CRISPR screens: Identify modifiers of APOL1 toxicity in podocytes, revealing potential therapeutic targets such as SIRT1 and AMPK.
• • Isogenic pairs: Wild-type vs. mutant lines allow precise measurement of allele-specific effects, reducing confounding from genetic background.

These studies provide causal evidence linking genetic alterations to disease phenotypes, accelerating target validation for drug discovery.

Isogenic cell pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. They allow identification of compounds that selectively target mutant cells while sparing wild-type cells, reducing toxicity.

Applications:

• • Screening for podocyte-protective agents: APOL1 G1 mutant podocytes are more sensitive to stress; screening libraries can identify compounds that rescue viability.
• • Resistance modeling: Chronic exposure of podocytes to glucocorticoids can induce resistance; gene-edited lines with CRISPR knockout of NR3C1 (glucocorticoid receptor) model steroid-resistant nephrotic syndrome.
• • Combination therapy: Isogenic lines with multiple mutations (e.g., APOL1 G1 + NPHS2 knockout) mimic complex disease and allow testing of combination regimens.
• • Personalized medicine: Patient-derived iPSCs edited to correct mutations can be used to test drug responses, guiding individualized therapy.

These approaches accelerate preclinical drug development and reduce attrition rates.

CRISPR synthetic lethality screens in gene-edited cells can uncover biomarkers and therapeutic targets. By introducing a disease-causing mutation (e.g., APOL1 G1) and then performing a genome-wide CRISPR knockout screen, researchers can identify genes that are essential for survival only in mutant cells.

Key findings:

• • Synthetic lethal partners of APOL1 G1: Knockout of SIRT1 or AMPK reduces mutant cell death, suggesting these as therapeutic targets.
• • Biomarkers of podocyte injury: CRISPR reporter lines with fluorescent tags for nephrin or podocin enable high-content screening for biomarkers.
• • Exosome-based biomarkers: Gene-edited podocytes release exosomes with specific miRNA profiles; these can be used as non-invasive biomarkers for disease progression.
• • Immune cell interactions: Co-culture of gene-edited podocytes with immune cells (e.g., T cells) can identify cytokine signatures as biomarkers of autoimmune GN.

These discoveries facilitate early diagnosis and monitoring of treatment response.

The following public databases provide valuable data for glomerulonephritis research, including genomic, transcriptomic, and clinical information.

These resources enable integrative analyses and support target discovery.